Bye bye Ozempic: Eli Lilly says its new drug retatrutide more than doubles weight loss — Live Feedhttps://www.live-feeds.com/feed/bye-bye-ozempic-eli-lilly-says-its-new-drug-retatrutide-more-than-doubles-weight-lossContinuously updated, source-cited coverage. Eli Lilly Says Retatrutide Beats Ozempic in Trialhttps://www.live-feeds.com/feed/bye-bye-ozempic-eli-lilly-says-its-new-drug-retatrutide-more-than-doubles-weight-losshttps://www.live-feeds.com/feed/bye-bye-ozempic-eli-lilly-says-its-new-drug-retatrutide-more-than-doubles-weight-loss#u165934Sat, 31 Oct 2026 12:55:49 +0000Eli Lilly reports that its experimental weekly injection retatrutide more than doubles the weight loss of Novo Nordisk's Ozempic at its highest approved dose. Results from a phase 3 head-to-head diabetes showdown show the next-generation medication also delivered superior blood sugar reduction, measured by A1C levels. Retatrutide is often called a triple-G drug because it mimics three hunger-regulating hormones. Eli Lilly anticipates filing a regulatory application for the drug in the first quarter of 2027.Why it mattersThe trial results strengthen Eli Lilly's competitive position in